INDIANAPOLIS and RIDGEFIELD, Conn., July
10, 2017 /PRNewswire/ -- Popular television host and
legendary entertainer, Don
Francisco, is joining Lilly and Boehringer Ingelheim to
launch a new awareness initiative, Basado en Hechos, to help
address common misconceptions about type 2 diabetes and insulin
treatment.
As part of this partnership, Don
Francisco, who is known for his ability to connect with his
audiences and inform them of the important issues of the day, will
head to cities across the country to share his own personal journey
of living with type 2 diabetes. These conversations will help to
educate communities on some of the facts about type 2 diabetes.
"I was diagnosed with type 2 diabetes 16 years ago, and at that
time I believed many things about diabetes that weren't correct.
These misconceptions prevented me from making the best decisions
for my health," states Don
Francisco. "I joined the Basado en Hechos initiative
to share what I've learned over the years with the 3.2 million
Hispanics in the U.S. living with diabetes.1 Together,
we can learn about the condition."
Today, Don Francisco has learned
to manage his type 2 diabetes daily through medication and healthy
lifestyle habits, allowing him to stay active and include the foods
he loves in his meal plan.
"As a Hispanic healthcare professional who has worked within our
community for many years, I've seen many patients who are hesitant
to start insulin due to misconceptions about insulin treatments and
diabetes management. One worry is that they will have to overhaul
their lifestyle," states Dr. Frank
Lavernia, Founder and Director of the North Broward Diabetes
Center, Pompano Beach, FL.
"Diabetes is a progressive condition that can change over time,
requiring adjustments in a person's treatment plan. For many, this
could include incorporating a once-daily insulin into their
treatment regimen. I encourage people in our community to have an
open conversation with their own healthcare providers to learn the
facts about diabetes and make informed choices that may be best for
their health."
Hispanics with type 2 diabetes are approximately 1.5 times less
likely to adhere to insulin therapy than non-Hispanic white
patients2, further evidence of the importance of being
informed about type 2 diabetes and available treatment options.
"The Hispanic community is disproportionately affected by
diabetes – the prevalence of total diabetes (diagnosed/undiagnosed)
among all Hispanic/Latino groups in the U.S. is 16.9%, compared to
10.2% for non-Hispanic whites adults3 – so diabetes
education in the Hispanic community is crucial," said Dr.
Dara Schuster, Senior Medical
Director at Lilly. "We are proud to partner with Don Francisco – someone who is incredibly
passionate about the cause and deeply connected to the Hispanic
community – to help us dispel myths and provide facts to those with
diabetes, their caregivers and families so they can make informed
decisions about their health and treatment plans."
Through the Basado en Hechos initiative, Don Francisco encourages people living with type
2 diabetes to start a conversation with their healthcare provider
about available treatment options.
To learn more about additional misconceptions about diabetes and
insulin, as well as information about a diabetes treatment, people
should visit www.basadoenhechos.com.
About Diabetes
Approximately 29 million
Americans4 and an estimated 415 million people
worldwide5 have diabetes, and nearly 28 percent of
Americans with diabetes — totaling eight million people — are
undiagnosed.4,5 In the U.S., approximately 12 percent of
those aged 20 and older have diabetes4. Type 2 diabetes
is the most common type, accounting for an estimated 90 to 95
percent of all diagnosed adult diabetes cases in the
U.S.4 Diabetes is a chronic condition that occurs when
the body either does not properly produce, or use, the hormone
insulin.
Boehringer Ingelheim and Eli Lilly and Company
In January 2011,
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced
an alliance in diabetes that centers on compounds representing
several of the largest diabetes treatment classes. The alliance
leverages the strengths of two of the world's leading
pharmaceutical companies. By joining forces, the companies
demonstrate commitment in the care of patients with diabetes and
stand together to focus on patient needs. Find out more about the
alliance at www.boehringer-ingelheim.com or www.lilly.com.
About Lilly Diabetes
Lilly has been a global leader
in diabetes care since 1923, when we introduced the world's first
commercial insulin. Today we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research and collaboration, a broad and
growing product portfolio and a continued determination to provide
real solutions—from medicines to support programs and more—we
strive to make life better for all those affected by diabetes
around the world. For more information, visit
www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels.
About Boehringer Ingelheim
Boehringer Ingelheim
Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary
of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's top 20 pharmaceutical
companies. Headquartered in Ingelheim, Germany, the company operates globally with
approximately 50,000 employees. Since its founding in 1885, the
company has remained family-owned and today creates value through
innovation for three business areas including human
pharmaceuticals, animal health and biopharmaceutical contract
manufacturing.
Boehringer Ingelheim is committed to improving lives and
providing valuable services and support to patients and their
families. Our employees create and engage in programs that
strengthen our communities. Please visit our website to learn more
about how we make more health for more people through our Corporate
Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about
$17.6 billion (15.9 billion euros). R&D expenditure
corresponds to 19.6 percent of its net sales.
For more information please visit www.boehringer-ingelheim.us,
or follow us on Twitter @BoehringerUS.
P-LLY
CONTACT:
Dani
Barnhizer
Lilly Diabetes
Email: dbarnhizer@lilly.com
Phone: (317) 607-6119
Christopher Wahlers
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: christopher.wahlers@boehringer-ingelheim.com
Phone: (203) 798-4375
PP-LD-US-1128 06/2017 ©Lilly USA, LLC 2017
References:
- Centers for Disease Control and Prevention. Summary Health
Statistics for U.S. Adults: National Health Interview Survey, 2012.
Atlanta, GA: U.S. Department of
Health and Human Services; 2014.
- Campos, C. (2007). Addressing Cultural Barriers to the
Successful Use of Insulin in Hispanics With Type 2 Diabetes.
Southern Medical Journal. Retrieved April
27, 2017, from
http://www.medscape.com/viewarticle/561831
- Diabetes Among Hispanics: All Are Not Equal. (n.d.). Retrieved
April 26, 2017, from
http://www.diabetes.org/newsroom/press-releases/2014/diabetes-among-hispanics-all-are-not-equal.html?referrer=https%3A%2F%2Fwww.google.com%2F
- International Diabetes Federation. IDF Diabetes Atlas. 7th ed.
Brussels, Belgium: International
Diabetes Federation; 2015. Retrieved on April 27, 2017, from
http://www.diabetesatlas.org/resources/2015-atlas.html.
- Centers for Disease Control and Prevention. National Diabetes
Statistics Report: Estimates of Diabetes and Its Burden in
the United States, 2014.
Atlanta, GA: U.S. Department of
Health and Human Services; 2014. Retrieved on April 27, 2017, from
http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
View original content with
multimedia:http://www.prnewswire.com/news-releases/renowned-television-personality-don-francisco-introduces-new-initiative-to-help-dispel-myths-about-diabetes-and-insulin-treatment-300484993.html
SOURCE Eli Lilly and Company